Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

222
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

205
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

QUALITY OF LIFE IN BREAST CANCER PATIENTS USING NEOADJUVANT AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN COMPARISON WITH PG (PACLITAXEL AND GEMCITABINE) THERAPY

Pages

  41-47

Abstract

 Background: QUALITY OF LIFE has become a part of the evaluation criteria for cancer therapy. The aim of this study was to evaluate the QUALITY OF LIFE in BREAST CANCER patients under chemotherapy regimens that contained DOXORUBICIN AND CYCLOPHOSPHAMIDE (AC) compared to paclitaxel and gemcitabine (PG).Methods: This cohort study evaluated 100 women with BREAST CANCER treated by DOXORUBICIN AND CYCLOPHOSPHAMIDE or GEMCITABINE AND PACLITAXEL regimens. We used the European Organization for Research and Treatment of Cancer QUALITY OF LIFE Questionnaire-Core 30 to assess health related QUALITY OF LIFE at the beginning and end of chemotherapy. Data were analyzed by the independent t-test at a significance level of 0.05.Results: Most of the 100 patients were married (68%), aged 41-50 years (36%), non-college educated (76%), and had insurance (97%). The mean QUALITY OF LIFE scores at the first session of chemotherapy and prior to the onset of treatment-related adverse events were 71.33 for the DOXORUBICIN AND CYCLOPHOSPHAMIDE groups and 71.15 for the GEMCITABINE AND PACLITAXEL groups. Analysis of the European Organization for Research and Treatment of Cancer QUALITY OF LIFE Questionnaire-Core 30 at the last chemotherapy session showed that the QUALITY OF LIFE in both groups deteriorated as a result of side effects. The mean of QUALITY OF LIFE scores at the first session of chemotherapy were 66.49 for the DOXORUBICIN AND CYCLOPHOSPHAMIDE group and 59.99 for the GEMCITABINE AND PACLITAXEL group.Conclusion: Strategies to improve the emotional and role functions of the patients who undergo treatment should be given priority. Financial difficulties faced by BREAST CANCER patients should be addressed from a policy making level at the initiating health financing system.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    REZAPOUR, AZIZ, JAVAN NOUGHABI, JAVAD, FARAMARZI, AHMAD, HARATI KHALILABAD, TOURAJ, VAHEDI, SAJJAD, & TEYMOURIZAD, ABEDIN. (2018). QUALITY OF LIFE IN BREAST CANCER PATIENTS USING NEOADJUVANT AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN COMPARISON WITH PG (PACLITAXEL AND GEMCITABINE) THERAPY. MIDDLE EAST JOURNAL OF CANCER, 9(1), 41-47. SID. https://sid.ir/paper/321191/en

    Vancouver: Copy

    REZAPOUR AZIZ, JAVAN NOUGHABI JAVAD, FARAMARZI AHMAD, HARATI KHALILABAD TOURAJ, VAHEDI SAJJAD, TEYMOURIZAD ABEDIN. QUALITY OF LIFE IN BREAST CANCER PATIENTS USING NEOADJUVANT AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN COMPARISON WITH PG (PACLITAXEL AND GEMCITABINE) THERAPY. MIDDLE EAST JOURNAL OF CANCER[Internet]. 2018;9(1):41-47. Available from: https://sid.ir/paper/321191/en

    IEEE: Copy

    AZIZ REZAPOUR, JAVAD JAVAN NOUGHABI, AHMAD FARAMARZI, TOURAJ HARATI KHALILABAD, SAJJAD VAHEDI, and ABEDIN TEYMOURIZAD, “QUALITY OF LIFE IN BREAST CANCER PATIENTS USING NEOADJUVANT AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN COMPARISON WITH PG (PACLITAXEL AND GEMCITABINE) THERAPY,” MIDDLE EAST JOURNAL OF CANCER, vol. 9, no. 1, pp. 41–47, 2018, [Online]. Available: https://sid.ir/paper/321191/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top